Literature DB >> 2828301

A comparison of the efficacy of itraconazole, amphotericin B and 5-fluorocytosine in the treatment of Aspergillus fumigatus endocarditis in the rabbit.

L P Longman1, M V Martin.   

Abstract

The efficacy of amphotericin B, 5-fluorocytosine and itraconazole was compared for the treatment of experimental rabbit Aspergillus fumigatus endocarditis. Therapy with amphotericin B or 5-fluorocytosine, at dosages of 3.0 and 35 mg/kg body weight respectively, failed to eradicate aspergillus from the cardiac vegetations in all but one of the animals tested; none of these animals survived for longer than nine treatment days. When similar doses of amphotericin and 5-fluorocytosine were administered concomittantly, 30% of the animals had sterile vegetations. Itraconazole at 2.5 and 3.5 mg/kg body weight was not successful; all the animals tested had infected vegetations and did not survive beyond nine days of therapy. In contrast, itraconazole at 5.0 mg/kg sterilised the endocardial vegetations and all these animals survived for 14 days. It is concluded that itraconazole may be useful in the treatment of aspergillus endocarditis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828301     DOI: 10.1093/jac/20.5.719

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

2.  Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.

Authors:  D T A te Dorsthorst; P E Verweij; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 3.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

4.  Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.

Authors:  M V Martin; J Yates; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 6.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

7.  Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease.

Authors:  S Kloss; A Schuster; H Schroten; J Lamprecht; V Wahn
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

8.  Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.

Authors:  T F Patterson; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 9.  Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Front Microbiol       Date:  2017-05-16       Impact factor: 5.640

10.  Identification of hydatidosis-related modules and key regulatory genes.

Authors:  Jijun Song; Mingxin Song
Journal:  PeerJ       Date:  2020-06-18       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.